Drug profile · INN
rituximab
RIXIMYO
rituximab (RIXIMYO) is a b-lymphocyte antigen cd20 binding agent. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — rituximab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- SUBCUTANEOUS
- Patents
- 5
- Programs
- 119
- Data quality
- 0.84
Quick answer
rituximab (RIXIMYO) is a b-lymphocyte antigen cd20 binding agent. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
B-lymphocyte antigen CD20 binding agent
Primary target: B-lymphocyte antigen CD20
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications
Lilly will present positive Phase 3 BRUIN CLL-322 results at the 2026 EHA Annual Meeting, comparing pirtobrutinib plus venetoclax and rituximab against venetoclax and rituximab. The presentation underscores Lilly's expanding hematology portfolio, bolstered by recent acquisitions of Ajax Therapeutics and Kelonia Therapeutics.
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Eli Lilly announces FDA approval of Foundayo (orforglipron) for obesity treatment alongside positive Phase 3 results and raised full-year guidance in Q1 2026.
Biosimilar Market Growth India: Key Drivers, Challenges & Opportunities
The biosimilar market in India is poised for significant growth, driven by increasing demand for affordable biologics like Trastuzumab, alongside various challenges and opportunities.
Pipeline programs
Related & competitor drugs
Related patents
-
US 11896617
Polynucleotides encoding rituximab-resistant chimeric antigen receptors
granted -
US 11352426
CD3 binding polypeptides
granted -
US 10307481
CD37 immunotherapeutics and uses thereof
granted -
US 10202452
CD3 binding polypeptides
granted -
US 10143748
B-cell reduction using CD37-specific and CD20-specific binding molecules
granted
Frequently asked questions
What is rituximab?
rituximab (RIXIMYO) is a b-lymphocyte antigen cd20 binding agent. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for rituximab?
RIXIMYO is a marketed brand name for rituximab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rituximab?
rituximab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.